%0 Journal Article
%T Everolimus-eluting coronary stents
%A Alejandro Saez
%A Raul Moreno
%J Medical Devices: Evidence and Research
%D 2010
%I Dove Medical Press
%R http://dx.doi.org/10.2147/MDER.S4422
%X olimus-eluting coronary stents Review (4155) Total Article Views Authors: Alejandro Saez, Raul Moreno Published Date September 2010 Volume 2010:3 Pages 51 - 56 DOI: http://dx.doi.org/10.2147/MDER.S4422 Alejandro Saez, Raul Moreno Division of Interventional Cardiology, University Hospital La Paz, Madrid, Spain Abstract: Bare metal stents enabled a reduction in the risk of early procedural complications and restenosis in comparison with balloon angioplasty alone, but introduced a new and device-specific iatrogenic condition, ie, in-stent restenosis due to increased neointimal hyperplasia. Sirolimus- and paclitaxel-eluting stents reduce restenosis and the need for new revascularizations in comparison with bare metal stents, although at the cost of a slight increase in the risk of late stent thrombosis and a need for prolonged dual antiplatelet therapy. Everolimus is an analog of sirolimus with an increased solubility. In this review, the currently available evidence for everolimus-eluting stents is revised, including randomized trials against bare metal stents, and head-to-head trials comparing this stent with other drug-eluting stents.
%K coronary stents
%K restenosis
%K everolimus
%K review
%U https://www.dovepress.com/everolimus-eluting-coronary-stents-peer-reviewed-article-MDER